Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Measles Vaccine | 5 | 2018 | 301 | 2.34 | Why? |
| Rubella virus | 3 | 2018 | 46 | 1.55 | Why? |
| Measles-Mumps-Rubella Vaccine | 3 | 2018 | 282 | 1.54 | Why? |
| Vaccines | 9 | 2021 | 3692 | 1.20 | Why? |
| Viral Vaccines | 8 | 2021 | 7560 | 1.19 | Why? |
| Measles | 3 | 2018 | 608 | 1.17 | Why? |
| Epitopes, B-Lymphocyte | 3 | 2021 | 1267 | 1.00 | Why? |
| Influenza Vaccines | 7 | 2020 | 2941 | 0.94 | Why? |
| Drug Packaging | 1 | 2020 | 33 | 0.87 | Why? |
| Vaccination Coverage | 3 | 2019 | 1249 | 0.85 | Why? |
| Immunity, Humoral | 5 | 2021 | 4849 | 0.82 | Why? |
| WT1 Proteins | 1 | 2018 | 15 | 0.74 | Why? |
| Bronchoscopes | 1 | 2020 | 168 | 0.73 | Why? |
| Anti-Vaccination Movement | 1 | 2019 | 74 | 0.72 | Why? |
| Antigens | 2 | 2018 | 267 | 0.72 | Why? |
| Comprehension | 1 | 2021 | 259 | 0.70 | Why? |
| Biological Variation, Population | 1 | 2018 | 69 | 0.70 | Why? |
| Membrane Cofactor Protein | 1 | 2017 | 12 | 0.69 | Why? |
| Histocompatibility Antigens | 1 | 2017 | 38 | 0.69 | Why? |
| Systems Biology | 1 | 2020 | 320 | 0.68 | Why? |
| Manuscripts as Topic | 1 | 2016 | 17 | 0.67 | Why? |
| Cytoskeletal Proteins | 1 | 2017 | 63 | 0.66 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2018 | 325 | 0.65 | Why? |
| B-Lymphocytes | 4 | 2021 | 4418 | 0.64 | Why? |
| Immunity, Cellular | 3 | 2021 | 3614 | 0.64 | Why? |
| Individuality | 1 | 2018 | 142 | 0.63 | Why? |
| Zika Virus Infection | 2 | 2021 | 1920 | 0.60 | Why? |
| Receptors, KIR | 1 | 2017 | 167 | 0.60 | Why? |
| Epitopes, T-Lymphocyte | 3 | 2021 | 2262 | 0.58 | Why? |
| Measles virus | 1 | 2017 | 194 | 0.58 | Why? |
| Polymorphism, Single Nucleotide | 3 | 2018 | 3607 | 0.56 | Why? |
| Vaccination | 13 | 2021 | 19050 | 0.53 | Why? |
| Hepatitis B virus | 1 | 2021 | 882 | 0.53 | Why? |
| Informed Consent | 1 | 2021 | 890 | 0.52 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.52 | Why? |
| Allergy and Immunology | 1 | 2016 | 240 | 0.50 | Why? |
| Hepatitis B | 1 | 2021 | 888 | 0.50 | Why? |
| Genome-Wide Association Study | 2 | 2018 | 1648 | 0.50 | Why? |
| Rubella | 1 | 2014 | 127 | 0.49 | Why? |
| Meningitis, Meningococcal | 1 | 2014 | 114 | 0.49 | Why? |
| Consumer Health Information | 1 | 2021 | 750 | 0.48 | Why? |
| Influenza, Human | 4 | 2019 | 10779 | 0.45 | Why? |
| Health Literacy | 1 | 2021 | 1078 | 0.43 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.43 | Why? |
| Social Behavior | 1 | 2019 | 882 | 0.42 | Why? |
| Decontamination | 1 | 2020 | 1196 | 0.42 | Why? |
| Antibodies, Viral | 9 | 2020 | 51949 | 0.42 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.41 | Why? |
| Poliomyelitis | 1 | 2014 | 263 | 0.40 | Why? |
| Immunization | 2 | 2020 | 2019 | 0.39 | Why? |
| Immunologic Memory | 2 | 2021 | 3362 | 0.39 | Why? |
| Decision Making | 2 | 2021 | 3132 | 0.38 | Why? |
| Zika Virus | 1 | 2021 | 1924 | 0.36 | Why? |
| Computational Biology | 2 | 2020 | 4514 | 0.34 | Why? |
| Disease Eradication | 1 | 2014 | 581 | 0.34 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.33 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.33 | Why? |
| Clinical Trials, Phase III as Topic | 2 | 2021 | 782 | 0.32 | Why? |
| Communicable Diseases, Emerging | 2 | 2020 | 2523 | 0.32 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.31 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.30 | Why? |
| Host-Pathogen Interactions | 3 | 2020 | 11041 | 0.28 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.28 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.28 | Why? |
| Guillain-Barre Syndrome | 1 | 2018 | 1495 | 0.28 | Why? |
| Vaccines, Subunit | 2 | 2021 | 1088 | 0.28 | Why? |
| Humans | 49 | 2021 | 930598 | 0.27 | Why? |
| Guidelines as Topic | 1 | 2016 | 2844 | 0.26 | Why? |
| Mass Vaccination | 1 | 2014 | 1101 | 0.26 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2018 | 2984 | 0.25 | Why? |
| Antibodies, Neutralizing | 4 | 2017 | 25288 | 0.24 | Why? |
| Health Policy | 2 | 2020 | 6242 | 0.24 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.22 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.22 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.22 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.21 | Why? |
| Drug Storage | 1 | 2020 | 125 | 0.20 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.20 | Why? |
| Hepatitis B Surface Antigens | 1 | 2021 | 305 | 0.19 | Why? |
| Hepatitis B Vaccines | 1 | 2021 | 245 | 0.19 | Why? |
| Vaccine Potency | 1 | 2020 | 339 | 0.19 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.19 | Why? |
| Orthomyxoviridae | 1 | 2008 | 1168 | 0.19 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.19 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.18 | Why? |
| Peptides | 2 | 2021 | 2513 | 0.18 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.18 | Why? |
| Immunization Programs | 3 | 2020 | 2006 | 0.18 | Why? |
| HLA Antigens | 1 | 2004 | 830 | 0.18 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.18 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.17 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.17 | Why? |
| Chick Embryo | 1 | 2018 | 249 | 0.17 | Why? |
| Receptors, Virus | 1 | 2014 | 5659 | 0.17 | Why? |
| Technology, Pharmaceutical | 1 | 2017 | 82 | 0.16 | Why? |
| Internship and Residency | 1 | 2018 | 4987 | 0.16 | Why? |
| Child | 9 | 2020 | 70012 | 0.16 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.15 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.15 | Why? |
| Mass Spectrometry | 1 | 2021 | 1165 | 0.15 | Why? |
| Journal Impact Factor | 1 | 2016 | 134 | 0.15 | Why? |
| Writing | 1 | 2016 | 123 | 0.14 | Why? |
| Receptors, Retinoic Acid | 1 | 2014 | 39 | 0.14 | Why? |
| Adolescent | 7 | 2019 | 86841 | 0.14 | Why? |
| Smokers | 1 | 2020 | 550 | 0.14 | Why? |
| Adenoviridae | 1 | 2020 | 1151 | 0.14 | Why? |
| United States | 6 | 2021 | 46150 | 0.14 | Why? |
| Poliovirus Vaccines | 1 | 2014 | 85 | 0.13 | Why? |
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2014 | 80 | 0.13 | Why? |
| Structure-Activity Relationship | 1 | 2020 | 2219 | 0.13 | Why? |
| Genetic Vectors | 1 | 2020 | 1600 | 0.13 | Why? |
| Adult | 10 | 2021 | 244371 | 0.13 | Why? |
| Review Literature as Topic | 1 | 2016 | 387 | 0.13 | Why? |
| Poliovirus | 1 | 2014 | 109 | 0.13 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.13 | Why? |
| Public Health Surveillance | 2 | 2019 | 3129 | 0.12 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.12 | Why? |
| Travel-Related Illness | 1 | 2020 | 1357 | 0.12 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.11 | Why? |
| Immunization Schedule | 1 | 2019 | 1305 | 0.11 | Why? |
| Young Adult | 6 | 2018 | 93724 | 0.11 | Why? |
| Anaphylaxis | 1 | 2021 | 940 | 0.11 | Why? |
| Lectins, C-Type | 1 | 2014 | 405 | 0.11 | Why? |
| Meningococcal Vaccines | 1 | 2014 | 225 | 0.11 | Why? |
| Cell Adhesion Molecules | 1 | 2014 | 472 | 0.11 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.11 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.11 | Why? |
| Geriatrics | 1 | 2020 | 947 | 0.11 | Why? |
| Male | 11 | 2021 | 367725 | 0.10 | Why? |
| Drug Approval | 1 | 2020 | 1325 | 0.10 | Why? |
| Female | 11 | 2021 | 380317 | 0.10 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.10 | Why? |
| Receptors, Cell Surface | 1 | 2014 | 586 | 0.10 | Why? |
| Uncertainty | 1 | 2021 | 1888 | 0.10 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.10 | Why? |
| Africa South of the Sahara | 1 | 2014 | 1335 | 0.09 | Why? |
| Age Factors | 3 | 2019 | 21039 | 0.09 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.09 | Why? |
| Adjuvants, Immunologic | 1 | 2018 | 1709 | 0.09 | Why? |
| Amino Acid Sequence | 1 | 2020 | 6049 | 0.09 | Why? |
| Needs Assessment | 1 | 2019 | 2352 | 0.09 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.09 | Why? |
| Genomics | 1 | 2020 | 3118 | 0.09 | Why? |
| Antibody Formation | 2 | 2017 | 4038 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.08 | Why? |
| Virus Attachment | 1 | 2014 | 1259 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.08 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.08 | Why? |
| Drug Industry | 1 | 2014 | 689 | 0.08 | Why? |
| Animals | 4 | 2020 | 78931 | 0.08 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Cell Line | 1 | 2021 | 12040 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.07 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.07 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Gene Expression | 1 | 2014 | 3332 | 0.06 | Why? |
| Histocompatibility Testing | 1 | 2004 | 219 | 0.06 | Why? |
| Vaccines, Attenuated | 1 | 2008 | 952 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.06 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.05 | Why? |
| International Cooperation | 1 | 2014 | 3436 | 0.05 | Why? |
| Apolipoprotein E4 | 1 | 2020 | 99 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Aged | 5 | 2020 | 215776 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.05 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Masks | 1 | 2021 | 8528 | 0.04 | Why? |
| Alleles | 1 | 2004 | 1557 | 0.04 | Why? |
| Pneumococcal Vaccines | 1 | 2003 | 571 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Interleukin-6 | 1 | 2014 | 7522 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Virus Internalization | 1 | 2014 | 7921 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Infant | 1 | 2018 | 30274 | 0.04 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Diabetes Complications | 1 | 2003 | 2358 | 0.03 | Why? |
| Double-Blind Method | 1 | 2021 | 5988 | 0.02 | Why? |
| Logistic Models | 1 | 2004 | 9089 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Diabetes Mellitus | 1 | 2003 | 8207 | 0.01 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2004 | 21571 | 0.01 | Why? |
| Child, Preschool | 1 | 2004 | 36283 | 0.01 | Why? |
| Middle Aged | 1 | 2018 | 270681 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| Quality Assurance, Health Care | 1 | 2003 | 596 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2018 | 29620 | 0.01 | Why? |
Poland's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(204)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(76)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_